Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases (2019 - 2025)

Historic Current Leases for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $4.8 million.

  • Autolus Therapeutics' Current Leases rose 3531.39% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 3531.39%. This contributed to the annual value of $3.0 million for FY2024, which is 4066.89% down from last year.
  • Autolus Therapeutics' Current Leases amounted to $4.8 million in Q3 2025, which was up 3531.39% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Current Leases ranged from a high of $6.2 million in Q2 2023 and a low of $3.0 million during Q1 2025
  • For the 5-year period, Autolus Therapeutics' Current Leases averaged around $4.4 million, with its median value being $4.3 million (2021).
  • Per our database at Business Quant, Autolus Therapeutics' Current Leases soared by 5597.0% in 2023 and then tumbled by 4066.89% in 2024.
  • Over the past 5 years, Autolus Therapeutics' Current Leases (Quarter) stood at $4.5 million in 2021, then rose by 13.14% to $5.0 million in 2022, then grew by 0.3% to $5.1 million in 2023, then crashed by 40.67% to $3.0 million in 2024, then soared by 61.04% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $3.3 million for Q2 2025, and $3.0 million during Q1 2025.